The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts
Metrics: PDF 2995 views | Full Text 15655 views | ?
Leonid Visochek1, Dikla Atias3, Itay Spektor3, Asher Castiel3, Talia Golan1,3 and Malka Cohen-Armon1,2
1 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel
2 Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv 69978, Israel
3 Oncology Institute, Sheba Medical Center, Ramat Gan 53621, Israel
Keywords: PJ34; pancreas cancer; stroma; PANC1 cancer xenografts
Received: May 21, 2019 Accepted: September 10, 2019 Published: October 22, 2019
Recent reports demonstrate an exclusive eradication of a variety of human cancer cells by the modified phenanthridine PJ34. Their eradication during mitosis is attributed to PJ34 preventing NuMA clustering in the mitotic spindle poles of human malignant cells, which is crucial for their normal mitosis. Here, the effect of PJ34 is tested in cell cultures and xenografts of human pancreas ductal adenocarcinoma. Evidence is presented for a substantial reduction (80–90%) of PANC1 cancer cells in xenografts, measured 30 days after the treatment with PJ34 has been terminated. Benign cells infiltrated into the PANC1 tumors (stroma) were not affected. Growth, weight gain and behavior of the treated nude mice were not impaired during, and 30 days after the treatment with PJ34. The efficient eradication of malignant cells in human pancreas cancer xenografts presents a new model of pancreas cancer treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.